Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Sponsor: Eli Lilly and Company
A PHASE3 clinical study on Chronic Migraine, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 17 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 12 earlier versions
-
Sep 2021 — Jun 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .